| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
|
Medicine details |
|
| Medicine name | dexamethasone (Ozurdex®) |
| Formulation | 700 micrograms intravitreal implant |
| Reference number | 510 |
| Indication | Treatment of adult patients with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion |
| Company | Allergan Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/07/2010 |
| NICE guidance | |